Yixintang Pharmaceutical - Public Comps and Valuation Multiples

Yixintang Pharmaceutical Overview

About Yixintang Pharmaceutical

Yixintang Pharmaceutical Group Co Ltd is a China-based company engages in the operation of pharmaceutical retail chains and wholesale businesses. Its products include traditional Chinese medicine, Western medicine, and medical equipment.

Founded

2000

HQ

Employees

n/a

Website

hx8886.com

Sectors

Pharmacies

Financials

LTM Revenue $2.6B

LTM EBITDA $132M

EV

$1.2B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Yixintang Pharmaceutical Financials

As of August 2025, Yixintang Pharmaceutical reported last 12-month revenue of $2.6B and EBITDA of $132M.

In the same period, Yixintang Pharmaceutical generated $805M in LTM gross profit and $61.1M in net income.

See Yixintang Pharmaceutical valuation multiples based on analyst estimates

Yixintang Pharmaceutical P&L

In the most recent fiscal year, Yixintang Pharmaceutical reported revenue of $2.5B and EBITDA of $226M.

Yixintang Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Yixintang Pharmaceutical valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$2.6B	XXX	$2.5B	XXX	XXX	XXX
Gross Profit	$805M	XXX	$802M	XXX	XXX	XXX
Gross Margin	31%	XXX	32%	XXX	XXX	XXX
EBITDA	$132M	XXX	$226M	XXX	XXX	XXX
EBITDA Margin	5%	XXX	9%	XXX	XXX	XXX
EBIT	$108M	XXX	$79.6M	XXX	XXX	XXX
EBIT Margin	4%	XXX	3%	XXX	XXX	XXX
Net Profit	$61.1M	XXX	$16.0M	XXX	XXX	XXX
Net Margin	2%	XXX	1%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Yixintang Pharmaceutical including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $2.6B. EBITDA for the last twelve months was $132M. In the most recent fiscal year, Yixintang Pharmaceutical achieved $2.5B in revenue and $226M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$2.6B	Analyst estimates available to subscribers	$2.5B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$805M	Analyst estimates available to subscribers	$802M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	30.7% gross margin	Analyst estimates available to subscribers	31.8% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$132M	Analyst estimates available to subscribers	$226M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	5.0% EBITDA margin	Analyst estimates available to subscribers	9.0% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$108M	Analyst estimates available to subscribers	$79.6M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	4.1% EBIT margin	Analyst estimates available to subscribers	3.2% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$61.1M	Analyst estimates available to subscribers	$16.0M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	2.3% net profit margin	Analyst estimates available to subscribers	0.6% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Yixintang Pharmaceutical

This financial data table provides comprehensive performance metrics for Yixintang Pharmaceutical, a company based in China. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Yixintang Pharmaceutical generated $2.6B in revenue over the last twelve months.
The company achieved $132M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $805M.
Net income over the last twelve months reached $61.1M.

Fiscal Year Performance

In the most recent fiscal year, Yixintang Pharmaceutical reported $2.5B in total revenue.
Fiscal year EBITDA was $226M.
The company maintained a gross profit margin of 31.8% in the most recent fiscal year.
EBITDA margin for the fiscal year was 9.0%.
Net profit margin reached 0.6% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Yixintang Pharmaceutical. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Yixintang Pharmaceutical Stock Performance

Yixintang Pharmaceutical has current market cap of CNY 8.8B (or $1.2B), and EV of CNY 8.5B (or $1.2B).

Market Cap Evolution

Yixintang Pharmaceutical Stock Data

As of September 15, 2025, Yixintang Pharmaceutical's stock price is CNY 15 (or $2).

See Yixintang Pharmaceutical trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$1.2B	$1.2B	XXX	XXX	XXX	XXX	$0.10

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Yixintang Pharmaceutical Valuation Multiples

Yixintang Pharmaceutical's trades at 0.5x EV/Revenue multiple, and 5.3x EV/EBITDA.

See valuation multiples for Yixintang Pharmaceutical and 15K+ public comps

Yixintang Pharmaceutical Financial Valuation Multiples

As of September 15, 2025, Yixintang Pharmaceutical has market cap of $1.2B and EV of $1.2B.

Equity research analysts estimate Yixintang Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Yixintang Pharmaceutical has a P/E ratio of 20.2x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$1.2B	XXX	$1.2B	XXX	XXX	XXX
EV (current)	$1.2B	XXX	$1.2B	XXX	XXX	XXX
EV/Revenue	0.5x	XXX	0.5x	XXX	XXX	XXX
EV/EBITDA	9.1x	XXX	5.3x	XXX	XXX	XXX
EV/EBIT	11.1x	XXX	15.0x	XXX	XXX	XXX
EV/Gross Profit	1.5x	XXX	n/a	XXX	XXX	XXX
P/E	20.2x	XXX	77.3x	XXX	XXX	XXX
EV/FCF	5.8x	XXX	5.8x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Yixintang Pharmaceutical Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Yixintang Pharmaceutical Margins & Growth Rates

Yixintang Pharmaceutical's last 12 month revenue growth is 8%

Yixintang Pharmaceutical's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.

Yixintang Pharmaceutical's rule of 40 is 20% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Yixintang Pharmaceutical's rule of X is 26% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Yixintang Pharmaceutical and other 15K+ public comps

Yixintang Pharmaceutical Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	8%	XXX	8%	XXX	XXX	XXX
EBITDA Margin	5%	XXX	9%	XXX	XXX	XXX
EBITDA Growth	23%	XXX	-27%	XXX	XXX	XXX
Rule of 40	20%	XXX	17%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	26%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	n/a	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	4%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	0%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	29%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial